Biotechs in Q2: For now, the trend is down
Interviewee/Contributor
William Ellington
Organisation
Evernow Publishing Ltd
Research Directory
Calliditas makes debut on Nasdaq Stockholm
Interviewee/ContributorRenée Aguiar-LucanderOrganisationCalliditas Therapeutics ABBuilding a culture of entrepreneurship in Nigeria
Interviewee/ContributorSelema AkuiyiboOrganisationSociety for Family Health NigeriaEU Commission proposes €100 billion for science
Interviewee/ContributorPeter CharlishOrganisationMedNousOrgans-on-chips enter the laboratories of big pharma
Interviewee/ContributorLorna Ewart and Geraldine HamiltonOrganisationAstraZeneca Plc and Emulate IncCombination therapy in oncology
Interviewee/ContributorGerben Moolhuizen and Kees MeliefOrganisationISA Pharmaceuticals BVASCO 2018: Oncology trials break new ground
Interviewee/ContributorBruno PagliaraThe myth of biotech self-determination
Interviewee/ContributorEdwin MosesOrganisationAblynx NVPharma slow to adopt SE incorporation
Interviewee/ContributorWilliam EllingtonOrganisationMedNousHow surrogate markers impact drug development
Interviewee/ContributorShiva MemariOrganisationVertical Knowing